New genetic test may guide better anti-HER2 treatment selection

[News]

A genetic test for PIK3CA mutations may help to identify patients with HER2-positive breast cancer who are less likely to benefit from combination anti-HER2 therapy, according to a study published...

More... (http://www.medicalnewstoday.com/releases/297842.php)